Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

413 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts.
Muso E, Endo T, Itabashi M, Kakita H, Iwasaki Y, Tateishi Y, Komiya T, Ihara T, Yumura W, Sugiyama T, Joh K, Suzuki K. Muso E, et al. Among authors: tateishi y. Clin Exp Nephrol. 2013 Oct;17(5):659-662. doi: 10.1007/s10157-012-0755-7. Epub 2012 Dec 21. Clin Exp Nephrol. 2013. PMID: 23263238 Free PMC article.
Role of hypoxia-inducible factor-1 in the development of renal fibrosis in mouse obstructed kidney: Special references to HIF-1 dependent gene expression of profibrogenic molecules.
Kabei K, Tateishi Y, Nozaki M, Tanaka M, Shiota M, Osada-Oka M, Nishide S, Uchida J, Nakatani T, Tomita S, Miura K. Kabei K, et al. Among authors: tateishi y. J Pharmacol Sci. 2018 Jan;136(1):31-38. doi: 10.1016/j.jphs.2017.12.004. Epub 2017 Dec 28. J Pharmacol Sci. 2018. PMID: 29352658 Free article.
Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model.
Kabei K, Tateishi Y, Shiota M, Osada-Oka M, Nishide S, Uchida J, Nakatani T, Matsunaga S, Yamaguchi T, Tomita S, Miura K. Kabei K, et al. Among authors: tateishi y. J Pharmacol Sci. 2020 Mar;142(3):93-100. doi: 10.1016/j.jphs.2019.12.002. Epub 2019 Dec 6. J Pharmacol Sci. 2020. PMID: 31866051 Free article.
Atherogenic Dyslipidemia Is Critically Related to Aortic Complicated Lesions in Cryptogenic Stroke.
Kikuno M, Ueno Y, Tateishi Y, Kuriki A, Doijiri R, Shimizu T, Takekawa H, Kanemaru K, Shimada Y, Yamaguchi E, Koga M, Kamiya Y, Ihara M, Tsujino A, Hirata K, Hasegawa Y, Aizawa H, Terashi H, Hattori N, Urabe T; CHALLENGE ESUS/CS collaborators. Kikuno M, et al. Among authors: tateishi y. J Atheroscler Thromb. 2024 Dec 26. doi: 10.5551/jat.65289. Online ahead of print. J Atheroscler Thromb. 2024. PMID: 39721702 Free article.
Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis.
Izumi R, Hashimoto T, Kisanuki H, Ikuta K, Otsuru W, Asakawa S, Yamamoto S, Misumi K, Fujino T, Shinohara K, Matsushima S, Hosokawa K, Katsuki S, Mori T, Hashisako M, Tateishi Y, Iwasaki T, Oda Y, Kinugawa S, Abe K. Izumi R, et al. Among authors: tateishi y. Cardiooncology. 2024 Nov 21;10(1):82. doi: 10.1186/s40959-024-00288-0. Cardiooncology. 2024. PMID: 39574216 Free PMC article.
413 results